How the protein FDXR in cell nuclei may help stop tumors
The nuclear Ferredoxin reductase and its role in tumor suppression
This project explores whether a protein called FDXR inside cell nuclei helps stop cancer cells from growing, which could help people with breast cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project ID | NIH-11324020 on NIH RePORTER |
What this research studies
Researchers will study what controls where FDXR sits inside cells and how nuclear FDXR affects cell growth and survival. They will use laboratory experiments on human breast cancer cell lines, molecular assays to map FDXR interactions with proteins like p53, and biochemical tests to track responses to DNA damage. The team may also analyze tumor samples to see how FDXR behaves in real patient tissue. Findings will clarify whether targeting FDXR-related pathways could be useful for some cancers.
Who could benefit from this research
Good fit: Ideal participants would be people with breast cancer who are able to donate tumor tissue, provide clinical information, or join future trials testing FDXR-related approaches.
Not a fit: Patients seeking immediate changes in their treatment or those with cancers not linked to FDXR pathways are unlikely to get direct benefit from this basic laboratory project.
Why it matters
Potential benefit: If successful, this work could identify new ways to restore tumor-suppressing activity and suggest targets for future breast cancer treatments.
How similar studies have performed: Previous laboratory work has shown FDXR responds to DNA damage and can influence cell death, but using this knowledge as a treatment strategy remains unproven.
Where this research is happening
Davis, United States
- University of California at Davis — Davis, United States (Active)
Researchers
- Principal investigator: Chen, Xinbin — University of California at Davis
- Study coordinator: Chen, Xinbin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.